PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-60.05M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.36× | Operating cash flow / net income. Period ending 2026-06-30. $-60.05M ÷ $-43.99M ≈ 1.36× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -60.05M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 54.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -43.99M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-60.05M | (m) | (m) | $54.53M | (m) | $-43.99M | (m) | (m) | (m) | 1.36× |
| 2026-03-31 | (m) | (m) | $-81.34M | (m) | (m) | $57.94M | (m) | $-151.18M | (m) | (m) | (m) | 0.54× |
| 2025-12-31 | (m) | (m) | $-163.58M | (m) | (m) | $9.68M | (m) | $-244.09M | (m) | (m) | (m) | 0.67× |
| 2025-09-30 | (m) | (m) | $-188.04M | (m) | (m) | $11.79M | (m) | $-280.46M | (m) | (m) | (m) | 0.67× |
| 2025-06-30 | (m) | (m) | $-192.66M | (m) | (m) | $10.34M | (m) | $-302.92M | (m) | (m) | (m) | 0.64× |
| 2025-03-31 | (m) | (m) | $-130.36M | (m) | (m) | $137.94M | (m) | $-110.27M | (m) | (m) | (m) | 1.18× |
| 2024-12-31 | (m) | (m) | $-150.05M | (m) | (m) | $135.16M | (m) | $-122.31M | (m) | (m) | (m) | 1.23× |
| 2024-09-30 | (m) | (m) | $-153.32M | (m) | (m) | $133.35M | (m) | $-131.83M | (m) | (m) | (m) | 1.16× |
| 2024-06-30 | (m) | (m) | $-98.61M | (m) | (m) | $217.25M | (m) | $-50.92M | (m) | (m) | (m) | 1.94× |
| 2024-03-31 | (m) | (m) | $-159.50M | (m) | (m) | $89.25M | (m) | $-172.40M | (m) | (m) | (m) | 0.93× |
| 2023-12-31 | (m) | (m) | $-133.91M | (m) | (m) | $91.37M | (m) | $-147.03M | (m) | (m) | (m) | 0.91× |
| 2023-09-30 | (m) | (m) | $-87.84M | (m) | (m) | $140.98M | (m) | $-73.20M | (m) | (m) | (m) | 1.20× |
| 2023-06-30 | (m) | (m) | $-128.53M | (m) | (m) | $57.63M | (m) | $-140.87M | (m) | (m) | (m) | 0.91× |
| 2023-03-31 | (m) | (m) | $-118.86M | (m) | (m) | $54.92M | (m) | $-127.52M | (m) | (m) | (m) | 0.93× |
| 2022-12-31 | (m) | (m) | $-108.82M | (m) | (m) | $53.91M | (m) | $-116.95M | (m) | (m) | (m) | 0.93× |
| 2022-09-30 | (m) | (m) | $-126.30M | (m) | (m) | $5.15M | (m) | $-156.48M | (m) | (m) | (m) | 0.81× |
| 2022-06-30 | (m) | (m) | $16.97M | (m) | (m) | $142.81M | (m) | $-1.47M | (m) | (m) | (m) | -11.58× |
| 2022-03-31 | (m) | (m) | $88.86M | (m) | (m) | $201.57M | (m) | $67.42M | (m) | (m) | (m) | 1.32× |
| 2021-12-31 | (m) | (m) | $92.61M | (m) | (m) | $200.58M | (m) | $66.97M | (m) | (m) | (m) | 1.38× |
| 2021-09-30 | (m) | (m) | $95.97M | (m) | (m) | $199.76M | (m) | $69.44M | (m) | (m) | (m) | 1.38× |
| 2021-06-30 | (m) | (m) | $-35.55M | (m) | (m) | $60.75M | (m) | $-70.39M | (m) | (m) | (m) | 0.51× |
| 2021-03-31 | (m) | (m) | $-90.86M | (m) | (m) | $872.00K | (m) | $-124.31M | (m) | (m) | (m) | 0.73× |
| 2020-12-31 | (m) | (m) | $-80.36M | (m) | (m) | $853.00K | (m) | $-111.14M | (m) | (m) | (m) | 0.72× |
| 2020-09-30 | (m) | (m) | $-75.76M | (m) | (m) | $749.00K | (m) | $-101.98M | (m) | (m) | (m) | 0.74× |
| 2020-06-30 | (m) | (m) | $-65.30M | (m) | (m) | $797.00K | (m) | $-90.85M | (m) | (m) | (m) | 0.72× |
| 2020-03-31 | (m) | (m) | $-58.70M | (m) | (m) | $769.00K | (m) | $-80.38M | (m) | (m) | (m) | 0.73× |
| 2019-12-31 | (m) | (m) | $-52.97M | (m) | (m) | $814.00K | (m) | $-77.68M | (m) | (m) | (m) | 0.68× |
| 2019-09-30 | (m) | (m) | $-59.73M | (m) | (m) | $752.00K | (m) | $-78.58M | (m) | (m) | (m) | 0.76× |
| 2019-06-30 | (m) | (m) | $-84.36M | (m) | (m) | $802.00K | (m) | $-83.69M | (m) | (m) | (m) | 1.01× |
| 2019-03-31 | (m) | (m) | $-14.13M | (m) | (m) | $914.00K | (m) | $-127.77M | (m) | (m) | (m) | 0.11× |
| 2018-12-31 | (m) | (m) | $-28.28M | (m) | (m) | $955.00K | (m) | $-155.65M | (m) | (m) | (m) | 0.18× |
| 2018-09-30 | (m) | (m) | $-46.55M | (m) | (m) | $990.00K | (m) | $-180.94M | (m) | (m) | (m) | 0.26× |
| 2018-06-30 | (m) | (m) | $-30.71M | (m) | (m) | $954.00K | (m) | $-208.78M | (m) | (m) | (m) | 0.15× |
| 2018-03-31 | (m) | (m) | $-124.92M | (m) | (m) | $27.49M | (m) | $-166.60M | (m) | (m) | (m) | 0.75× |
| 2017-12-31 | (m) | (m) | $-131.18M | (m) | (m) | $27.52M | (m) | $-153.24M | (m) | (m) | (m) | 0.86× |
| 2017-09-30 | (m) | (m) | $-126.48M | (m) | (m) | $27.46M | (m) | $-154.38M | (m) | (m) | (m) | 0.82× |
| 2017-06-30 | (m) | (m) | $-138.81M | (m) | (m) | $27.53M | (m) | $-145.23M | (m) | (m) | (m) | 0.96× |
| 2017-03-31 | (m) | (m) | $-130.05M | (m) | (m) | $1.05M | (m) | $-167.97M | (m) | (m) | (m) | 0.77× |
| 2016-12-31 | (m) | (m) | $-117.27M | (m) | (m) | $1.05M | (m) | $-160.11M | (m) | (m) | (m) | 0.73× |
| 2016-09-30 | (m) | (m) | $-102.95M | (m) | (m) | $1.19M | (m) | $-135.36M | (m) | (m) | (m) | 0.76× |
| 2016-06-30 | (m) | (m) | $-89.28M | (m) | (m) | $1.33M | (m) | $-115.10M | (m) | (m) | (m) | 0.78× |
| 2016-03-31 | (m) | (m) | $-72.89M | (m) | (m) | $1.28M | (m) | $-92.93M | (m) | (m) | (m) | 0.78× |
| 2015-12-31 | (m) | (m) | $-62.45M | (m) | (m) | $1.61M | (m) | $-80.61M | (m) | (m) | (m) | 0.77× |
| 2015-09-30 | (m) | (m) | $-55.30M | (m) | (m) | $3.31M | (m) | $-69.56M | (m) | (m) | (m) | 0.79× |
| 2015-06-30 | (m) | (m) | $-50.65M | (m) | (m) | $4.37M | (m) | $-59.77M | (m) | (m) | (m) | 0.85× |
| 2015-03-31 | (m) | (m) | $-33.30M | (m) | (m) | $19.21M | (m) | $-40.20M | (m) | (m) | (m) | 0.83× |
| 2014-12-31 | (m) | (m) | $-683.00K | (m) | (m) | $50.85M | (m) | $-7.15M | (m) | (m) | (m) | 0.10× |
| 2014-09-30 | (m) | (m) | $2.00M | (m) | (m) | (m) | (m) | $-5.09M | (m) | (m) | (m) | -0.39× |
| 2014-06-30 | (m) | (m) | $3.96M | (m) | (m) | (m) | (m) | $-1.60M | (m) | (m) | (m) | -2.48× |
| 2014-03-31 | (m) | (m) | $-9.10M | (m) | (m) | (m) | (m) | $-14.19M | (m) | (m) | (m) | 0.64× |
| 2013-12-31 | (m) | (m) | $-32.10M | (m) | (m) | (m) | (m) | $-41.00M | (m) | (m) | (m) | 0.78× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $-42.07M | (m) | (m) | (m) | (m) | $-41.41M | (m) | (m) | (m) | 1.02× |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $-19.70M | (m) | (m) | (m) | (m) | $-29.67M | (m) | (m) | (m) | 0.66× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |